Ernexa Therapeutics (NASDAQ:ERNA) Announces Earnings Results

Ernexa Therapeutics (NASDAQ:ERNA) released its earnings results on Thursday. The company reported ($3.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($3.30) by ($0.10), FiscalAI reports.

Ernexa Therapeutics Stock Performance

Shares of Ernexa Therapeutics stock traded down $0.15 on Friday, hitting $4.21. The stock had a trading volume of 25,279 shares, compared to its average volume of 1,388,595. The stock has a 50 day moving average of $5.88 and a 200 day moving average of $8.85. The firm has a market capitalization of $4.93 million, a P/E ratio of -0.16 and a beta of 2.57. Ernexa Therapeutics has a twelve month low of $3.18 and a twelve month high of $71.50.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the stock. Brookline Capital Markets initiated coverage on shares of Ernexa Therapeutics in a research note on Thursday, May 7th. They issued a “buy” rating and a $30.00 price target on the stock. Wall Street Zen cut shares of Ernexa Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday. Weiss Ratings reissued a “sell (e+)” rating on shares of Ernexa Therapeutics in a research note on Friday, July 17th. Finally, Zacks Research upgraded shares of Ernexa Therapeutics to a “hold” rating in a research report on Monday, May 11th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $30.00.

Institutional Investors Weigh In On Ernexa Therapeutics

A hedge fund recently bought a new position in Ernexa Therapeutics stock. Susquehanna International Group LLP purchased a new position in shares of Ernexa Therapeutics Inc. (NASDAQ:ERNA) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 30,854 shares of the company’s stock, valued at approximately $34,000. Susquehanna International Group LLP owned 0.39% of Ernexa Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). 70.55% of the stock is owned by institutional investors and hedge funds.

About Ernexa Therapeutics

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc was founded in 2018 and is based in Cambridge, Massachusetts.